Morgan Stanley recently shocked investors by claiming that Shake Shack stock (NYSE: SHAK) was too expensive. The investment firm claimed that SHAK offered "brand related optimism that is not supported by fundamentals."
We couldn't agree more.
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
Morgan Stanley recently shocked investors by claiming that Shake Shack stock (NYSE: SHAK) was too expensive. The investment firm claimed that SHAK offered "brand related optimism that is not supported by fundamentals."
We couldn't agree more.
Here are the top two takeaways from Shake Shack's shakeout...
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
Morgan Stanley recently shocked investors by claiming that Shake Shack stock (NYSE: SHAK) was too expensive. The investment firm claimed that SHAK offered "brand related optimism that is not supported by fundamentals."
We couldn't agree more.
Here are the top two takeaways from Shake Shack's shakeout...
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
This week's trading featured a three-day losing streak for U.S. markets on fears that the Fed may hike interest rates earlier than expected, with the Dow, S&P 500, and Nasdaq shedding 1.24%, 1.5%, and 1.57% respectively.
Bring it on!
I've pointed out repeatedly since the financial crisis began that the "good is bad" meme followed by traders - which triggers market dips with every piece of significant good news, thanks to paranoia that the Fed will seize on that news to raise rates - only creates buying opportunities for investors with the right tactics.
Today, that could be you.
The week's collapse creates three massive opportunities. I'm going to explain to you exactly what they are, why they exist, and most importantly, why they're being overlooked by insiders and mainstream investors alike.
Here's what they're all missing - and here's your opportunity...
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
The first U.S. case of the deadly Ebola virus has been confirmed in a patient in Dallas, Texas, and the news sent "Ebola stocks" - the companies racing to get approval for treatment - up as much as 20% in after-hours trading Tuesday.
But instead of trying to guess which company is going to come through with a cure, I recommend you concentrate on companies making the best medical testing, diagnosis, and drug delivery systems.
Like this one – it’s going to power sharply higher in the next 12 months…
By Diane Alter, Contributing Writer, Money Morning -
It's been a good year to own stocks, with markets hitting record highs. But investors holding dividend stocks have profited the most.
Even better, if the market pulls back from those record highs, dividend stocks typically perform better during a correction than non-dividend paying stocks.
To continue reading, please click here...